Dr Sanjeev also confirmed the supply agreement for the vaccine that Prime Minister Tan Sri Muhyiddin Yassin announced yesterday. In which would provide enough vaccination coverage for roughly 10 per cent of Malaysians.
Under the agreement, AstraZeneca will expand its global manufacturing capacity to make sure a dedicated supply of AZD1222 for Malaysia.
This takes place in parallel to the ongoing clinical trials within the U.S., the UK, Brazil, South Africa, Japan and Russia.
An interim analysis of the phase III clinical trial programme conducted by Oxford with AZD1222, peer-reviewed and published in medical journal The Lancet on December 8, has indicated the vaccine is safe and effective at preventing symptomatic Covid-19 also as protecting against severe disease and hospitalization.
To this end, AstraZeneca is working along with the Health Ministry. Together with the Science, Technology and Innovation Ministry on the preparations for swift and science-led regulatory approval.
The vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus). That causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein.
After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
- Malaysia PM Muhyiddin is the first in the country to use the COVID-19 vaccine
- Facebook removes anti-vaccine ‘fake news’ in Israel, government says